news
Digital growth focus of Sanofi’s new Digital Accelerator
Sanofi announces first Digital Accelerator to develop products and solutions that foster the use of digital, data and artificial intelligence.
List view / Grid view
Bioproduction
news
Detecting and eradicating mycoplasmas in ATMP cell lines
Here, EPR summarises the key points of Tim Sandle’s recent review of mycoplasma risks, detection and eradication techniques for cell cultures.
news
Collaboration between Lonza and IBF to progress Israeli biologics sector
Israel Biotech Fund (IBF) and Lonza announce agreement to accelerate the development and manufacture of Israeli biologics and small molecules.
podcasts
EPR Podcast Episode 11 – Developing vaccine technologies – Giulia Giordano and Mark Doherty, GSK
Why is vaccine manufacturing becoming more biological? How could Generalized Modules for Membrane Antigens (GMMA) enhance vaccinology? What developments have there been in adjuvant systems? Discover all this and more in this podcast with GSK experts.
news
Sanofi begins construction of Singapore vaccine facility
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
article
The future of CMC for novel therapies
Novel and advanced therapies have come on in leaps and bounds over the past decade. Some cell and gene therapies have already reached the approvals stage, while others have now entered the later development stages. As a result, manufacturing process consistency, GMP standards and more must now meet more formal…
article
Essential requirements for autologous cellular therapies
Edward Samuel, EVP Technical Operations at Achilles Therapeutics, explains why industrialised manufacturing and scale-up of autologous cellular immunotherapies will require fully closed systems and process automation.
news
WuXi Biologics awarded for excellence
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and Safety accolade for the second time at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
article
Bioprocessing/Bioproduction In-Depth Focus 2022
Download this in-depth focus to discover why closed systems and process automation are key for industrialised autologous cell therapy manufacturing and how CMC strategies for cell and gene therapies need to evolve.
article
European Pharmaceutical Review Issue 2 2022
Features in this issue discuss how bioprocessing must adapt to meet the needs of autologous cell therapies, the role of mass spectrometry in enhancing antibody consistency and the economic benefits of embracing continuous manufacturing. Also in this journal, articles exploring the development of precision medicine for chronic diseases, why acoustic…
news
Moderna and ROVI face further particulate problems with Spikevax®
A lot of Moderna’s Spikevax® vaccine is being recalled due to particulates, just six months after previous contamination concerns were supposedly solved.
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm-300x278.jpg)
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm.jpg)
news
Recipharm builds biologics presence with acquisitions
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
news
FUJIFILM acquires new cell therapy manufacturing facility
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
news
UK cell and gene therapy manufacturing challenge ends in success
In a £1.3 million collaborative project Symbiosis and the Cell and Gene Therapy (CGT) Catapult reduced viral vector manufacturing times by more than 25 percent.
news
Implantable technology could enable in vivo CAR T therapy
Pre-clinical research demonstrates the potential of a new implantable biotechnology called MASTER to produce and release CAR T cells in vivo.
